CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-0160
Issued: 2026-09-06

PRODUCT IDENTIFICATION

PRODUCT MOTS-c 10mg	SKU / INTERNAL CODE CRF-2026-0160	PRESENTATION Lyophilised powder, 10mg vial
BATCH NUMBER CRF-2026-0160	SAMPLE RECEIVED 2026-08-30	PRODUCTION DATE 2026-08-25
ANALYSIS DATE 2026-09-04	EXPIRY / RETEST DATE 2028-09-04	MOLECULAR FORMULA C101H152N28O22S2
MOLECULAR WEIGHT (G/MOL) 2174.58	CAS 1627580-64-6	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT Agilent 1290	COLUMN C18 4.6×150mm	COLUMN TEMPERATURE 35°C
MOBILE PHASE A 0.1% TFA H2O	MOBILE PHASE B ACN	FLOW RATE 1.0 mL/min
DETECTION WAVELENGTH 214 nm	INJECTION VOLUME 10 µL	SAMPLE CONCENTRATION 1.0 mg/mL
DILUENT —	RETENTION TIME (MAIN PEAK) 8.2 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · LAL · ICP-MS

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.4%	PASS
Identity (LC-MS)	2174.6 ±2%	Obs: 2174.5 [M+H]+	PASS

Test	Acceptance Criteria	Result	Verdict
Quantity found	95.0–105.0%	9.87 mg (98.7%)	PASS
Endotoxin	<1.0 EU/mg	<0.25 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Category: Longevity. Sample conforms to label claim and Gold panel acceptance criteria.

crafa

CRAFA